Spruce Biosciences appoints Adrian Quartel as Chief Medical Officer

SPRUCE BIOSCIENCES, INC.

Dr. Quartel replaces Dr. Kirk Ways, who had been serving as Interim CMO; Dr. Ways remains on the Board.
Quartel brings 25+ years pharma experience, most recently CMO of Zevra Therapeutics.
He previously led global medical affairs at BioMarin, launching six rare-disease treatments.
Quartel holds an M.D. from Erasmus University and is board certified in pharmaceutical medicine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.